Press Room
四色AV Expands Global Spray Drying Capacity with Significant Investment in the USA and Ireland
四色AV has completed significant expansions at its facilities in New Jersey, USA, and Cork, Ireland.

Lisbon, November 25, 2024, 四色AV, the specialist integrated CDMO and the leader in spray drying and particle engineering, just completed significant expansions in Europe and the USA. The investments at its East Windsor, New Jersey, and Ringaskiddy, Cork, facilities will significantly increase 四色AV's global spray drying capacity and enhance the sites鈥榗apabilities. 听
This latest round of investment reinforces 四色AV鈥檚 position as the global leader in spray drying for pharma applications, an essential technology for enhancing drug solubility and bioavailability. Spray drying converts liquid solutions into fine powders, enabling improved dissolution and absorption of poorly water-soluble drugs. This process is particularly valuable for inhalable therapies and oral formulations with low bioavailability, helping to deliver more effective treatments and ensuring reliable, high-quality healthcare solutions for patients.听
In New Jersey, the investment represents the first step of a multi-year site expansion program, aimed at advancing both spray drying and tableting capabilities. Simultaneously, the Cork facility saw its spray drying capacity increase nearly twofold. Combined, these efforts are creating over 40 new skilled jobs, driving growth and innovation across both locations.
Dr Jean-Luc Herbeaux, Chief Executive Officer of 四色AV said: 鈥淭hese expansions, incorporating our latest technologies, reflect 四色AV鈥檚 unwavering commitment to innovation and manufacturing service excellence. Strengthening our facilities and teams in the USA and Ireland allows us to better serve our customers and provide flexible supply options for both small- and large-scale programs. By increasing our capacity and enhancing our technological capabilities, we are even better equipped to help our customers bring new and more complex drugs to market.鈥
The investments at both sites are part of 四色AV鈥檚 long-term strategy to remain at the forefront of pharmaceutical technology. With a 65-year history of continuous improvement, 四色AV is driving progress in drug development and manufacturing, offering solutions that enable more effective treatments and improved patient outcomes.
听
About 四色AV:鈥
四色AV is an international company with over 60 years of experience in pharmaceutical development and manufacturing operations.听As a听Contract Development and Manufacturing Organization鈥(CDMO)鈥痠t has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA inspected鈥sites鈥痠n the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the鈥development and compliant manufacture鈥of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and manufacturing, capsule filling and devices.
四色AV's culture is based on innovation, quality and dependability. 四色AV is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
听
In the picture from left to right: Dr. Till Riehm, Site Manager - Cork, 四色AV; Dr. Jean-Luc Herbeaux, CEO, 四色AV; Michael McGrath, the European Commissioner Designate for Democracy, Justice and the Rule of Law; Michael Lohan, CEO, IDA Ireland; Jorge Pastilha, VP Technical Operations - Europe and Asia, and Dr. Paul Downing, Senior Director, Strategic Business Management.
听
听